COX-2 inhibitors as adjunctive therapy in schizophrenia: Rationale for use and evidence to date

Michael Riedel, Martin Strassnig, Markus J. Schwarz, Norbert Müller

Research output: Contribution to journalReview article

34 Scopus citations

Abstract

A better understanding of the human immune system and its complex interactions has resulted in new insights into the pathoaetiological mechanisms of psychiatric disorders. As a result, new treatment options are being explored. Several findings suggest that an imbalanced immune response is involved in the pathophysiology of schizophrenia. COX-2 inhibitors are known to influence the immune system in a way that may redirect this imbalance. Based on these suggestions, the COX-2 inhibitor celecoxib has been tested as a possible adjunctive therapeutic approach in the treatment of schizophrenia. While the first trial using celecoxib as add-on therapy to an atypical antipsychotic showed a significant beneficial effect, recent studies demonstrated that this effect may be limited to patients with recent-onset schizophrenia.

Original languageEnglish (US)
Pages (from-to)805-819
Number of pages15
JournalCNS Drugs
Volume19
Issue number10
DOIs
StatePublished - Dec 1 2005

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'COX-2 inhibitors as adjunctive therapy in schizophrenia: Rationale for use and evidence to date'. Together they form a unique fingerprint.

  • Cite this